journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/27987650/psychometric-properties-of-the-four-item-morisky-green-levine-medication-adherence-scale-among-atherosclerosis-risk-in-communities-aric-study-participants
#1
Hadi Beyhaghi, Bryce B Reeve, Jo E Rodgers, Sally C Stearns
OBJECTIVES: To evaluate the reliability and factorial validity of the four-item Morisky Green Levine Medication Adherence Scale (MGLS) among Atherosclerosis Risk in Communities (ARIC) Study participants. METHODS: We used the cross-sectional visit 5 data from the ARIC Study to assess the measurement properties of the MGLS. We measured the internal consistency using Cronbach α (where α > 0.70 is considered reliable for group-level measurement), the response frequency, and the inter item correlation...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987649/cost-effectiveness-of-a-national-opportunistic-screening-program-for-atrial-fibrillation-in-ireland
#2
Patrick S Moran, Conor Teljeur, Patricia Harrington, Susan M Smith, Breda Smyth, Joseph Harbison, Charles Normand, Máirín Ryan
OBJECTIVES: To evaluate the cost-effectiveness of a national atrial fibrillation screening program in Ireland involving annual opportunistic pulse palpation of all those older than 65 years during general practitioner consultations, with an electrocardiogram being performed if an irregular pulse is detected. METHODS: A probabilistic Markov model was used to simulate costs and clinical outcomes in a hypothetical cohort of men and women with and without screening over the course of 25 years, using a societal perspective...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987648/life-expectancy-and-lifetime-health-care-expenditures-for-type-1-diabetes-a-nationwide-longitudinal-cohort-of-incident-cases-followed-for-14-years
#3
Huang-Tz Ou, Chen-Yi Yang, Jung-Der Wang, Jing-Shiang Hwang, Jin-Shang Wu
OBJECTIVES: To assess additional life expectancy (LE), expected years of life lost , and lifetime health care expenditures after type 1 diabetes diagnosis, stratified by sex and age of first diagnosis (early: 0-12 years; late: 13-40 years). METHODS: A longitudinal cohort of patients with diabetes was constructed from Taiwan's National Health Insurance Research Database of 1999 to 2012. The survival functions for diabetic patients and age- and sex-matched general population were estimated by using a semiparametric extrapolation method with annual life tables...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987647/cost-effectiveness-of-quadrivalent-versus-trivalent-influenza-vaccine-in-the-united-states
#4
Pieter T de Boer, Pascal Crépey, Richard J Pitman, Bérengère Macabeo, Ayman Chit, Maarten J Postma
BACKGROUND: Designed to overcome influenza B mismatch, new quadrivalent influenza vaccines (QIVs) contain one additional B strain compared with trivalent influenza vaccines (TIVs). OBJECTIVE: To examine the expected public health impact, budget impact, and incremental cost-effectiveness of QIV versus TIV in the United States. METHODS: A dynamic transmission model was used to predict the annual incidence of influenza over the 20-year-period of 2014 to 2034 under either a TIV program or a QIV program...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987646/node-splitting-generalized-linear-mixed-models-for-evaluation-of-inconsistency-in-network-meta-analysis
#5
Tu Yu-Kang
BACKGROUND: Network meta-analysis for multiple treatment comparisons has been a major development in evidence synthesis methodology. The validity of a network meta-analysis, however, can be threatened by inconsistency in evidence within the network. One particular issue of inconsistency is how to directly evaluate the inconsistency between direct and indirect evidence with regard to the effects difference between two treatments. A Bayesian node-splitting model was first proposed and a similar frequentist side-splitting model has been put forward recently...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987645/health-economics-as-rhetoric-the-limited-impact-of-health-economics-on-funding-decisions-in-four-european-countries
#6
Margreet Franken, Emelie Heintz, Andreas Gerber-Grote, James Raftery
BACKGROUND: A response to the challenge of high-cost treatments in health care has been economic evaluation. Cost-effectiveness analysis presented as cost per quality-adjusted life-years gained has been controversial, raising heated support and opposition. OBJECTIVES: To assess the impact of economic evaluation in decisions on what to fund in four European countries and discuss the implications of our findings. METHODS: We used a protocol to review the key features of the application of economic evaluation in reimbursement decision making in England, Germany, the Netherlands, and Sweden, reporting country-specific highlights...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987644/using-patient-reported-outcomes-for-economic-evaluation-getting-the-timing-right
#7
Chris Schilling, Michelle M Dowsey, Philip M Clarke, Peter F Choong
BACKGROUND: Patient-reported outcome measures (PROMs) are becoming increasingly popular in orthopedic surgery. Preoperative and postoperative follow-up often elicit PROMs in the form of generic quality-of-life instruments (e.g., Short Form health survey SF-12 [SF-12]) that can be used in economic evaluation to estimate quality-adjusted life-years (QALYs). However, the timing of postoperative measurement is still under debate. OBJECTIVES: To explore the timing of postoperative PROMs collection and the implications for bias in QALY estimation for economic evaluation...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987643/cancer-care-coordinators-to-improve-tamoxifen-persistence-in-breast-cancer-how-heterogeneity-in-baseline-prognosis-impacts-on-cost-effectiveness
#8
Nisha Nair, Giorgi Kvizhinadze, Tony Blakely
OBJECTIVES: To assess the cost-effectiveness of a cancer care coordinator (CCC) in helping women with estrogen receptor positive (ER+) early breast cancer persist with tamoxifen for 5 years. METHODS: We investigated the cost-effectiveness of a CCC across eight breast cancer subtypes, defined by progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, and local/regional spread. These subtypes range from excellent to poorer prognoses...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987642/country-level-cost-effectiveness-thresholds-initial-estimates-and-the-need-for-further-research
#9
Beth Woods, Paul Revill, Mark Sculpher, Karl Claxton
BACKGROUND: Cost-effectiveness analysis can guide policymakers in resource allocation decisions. It assesses whether the health gains offered by an intervention are large enough relative to any additional costs to warrant adoption. When there are constraints on the health care system's budget or ability to increase expenditures, additional costs imposed by interventions have an "opportunity cost" in terms of the health foregone because other interventions cannot be provided. Cost-effectiveness thresholds (CETs) are typically used to assess whether an intervention is worthwhile and should reflect health opportunity cost...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987641/the-international-decision-support-initiative-reference-case-for-economic-evaluation-an-aid-to-thought
#10
Thomas Wilkinson, Mark J Sculpher, Karl Claxton, Paul Revill, Andrew Briggs, John A Cairns, Yot Teerawattananon, Elias Asfaw, Ruth Lopert, Anthony J Culyer, Damian G Walker
BACKGROUND: Policymakers in high-, low-, and middle-income countries alike face challenging choices about resource allocation in health. Economic evaluation can be useful in providing decision makers with the best evidence of the anticipated benefits of new investments, as well as their expected opportunity costs-the benefits forgone of the options not chosen. To guide the decisions of health systems effectively, it is important that the methods of economic evaluation are founded on clear principles, are applied systematically, and are appropriate to the decision problems they seek to inform...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987640/how-to-get-cost-effectiveness-analysis-right-the-case-of-vaccine-economics-in-latin-america
#11
Amanda Glassman, Oscar Cañón, Rachel Silverman
BACKGROUND: In middle-income countries, vaccines against pneumococcal disease, rotavirus, and human papilloma virus are in general more costly, not necessarily cost saving, and less consistently cost-effective than earlier generation vaccines against measles, diphtheria, tetanus, and pertussis. Budget impact is also substantial; public spending on vaccines in countries adopting new vaccines is, on average, double the amount of countries that have not adopted. Policymakers must weigh the costs and benefits of the adoption decision carefully, given the low coverage of other kinds of cost-effective health and nonhealth interventions in these same settings and relatively flat overall public spending on health as a share of gross domestic product (GDP) over time...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987639/making-choices-on-the-journey-to-universal-health-care-coverage-from-advocacy-to-analysis
#12
Kalipso Chalkidou, Anthony J Culyer
XXX.
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987638/from-the-co-editors-in-chief
#13
LETTER
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987637/erratum
#14
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987636/erratum
#15
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987635/erratum
#16
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987634/a-differential-item-functioning-analysis-of-the-eq-5d-in-cancer
#17
Adam B Smith, Kim Cocks, David Parry, Matthew Taylor
OBJECTIVES: To determine whether differential item functioning (DIF) was present in the EuroQol five-dimensional questionnaire (EQ-5D) used in cancer (non-small cell lung cancer and prostate cancer). METHODS: The Partial Credit Model was applied to the three-level version of the EQ-5D with data obtained from four randomized controlled trials in prostate cancer and non-small cell lung cancer completed at baseline before treatment (N = 2213). DIF was assessed across cancer type (two levels), sex (two levels), and age group (three levels) using Mantel-Haenszel chi-square statistics and evaluated against the Educational Testing Service classification rules...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987633/update-to-the-report-of-nationally-representative-values-for-the-noninstitutionalized-us-adult-population-for-five-health-related-quality-of-life-scores
#18
Janel Hanmer, Robert M Kaplan
BACKGROUND: The most recent reports of nationally representative health-related quality-of-life (HRQOL) values for the United States used data that were collected over a decade ago. OBJECTIVES: To update these values using data from 2011, stratified by age and sex. METHODS: This study used data from two sources-the 2011 Medical Expenditures Panel Survey (MEPS) and the 2011 National Health Interview Survey (NHIS). Both are nationally representative surveys of the US noninstitutionalized civilian population...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987632/the-cost-of-costing-treatments-incorrectly-errors-in-the-application-of-drug-prices-in-economic-evaluation-due-to-failing-to-account-for-the-distribution-of-patient-weight
#19
Anthony J Hatswell, Joshua Porter, Dawn Lee, Nadine Hertel, Nicholas R Latimer
BACKGROUND: The cost of pharmaceuticals dosed by weight or body surface area (BSA) can be estimated in several ways for economic evaluations. A review of 20 recent National Institute for Health and Care Excellence appraisals showed that 17 of them took the mean weight or BSA of patients, 2 costed the individual patient data from trials, and 2 fitted a distribution to patient-level data. OBJECTIVES: To investigate the estimated drug costs using different methodologies to account for patient characteristics for pharmaceuticals with a weight- or BSA-based posology...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27987631/economic-evaluations-of-multicomponent-disease-management-programs-with-markov-models-a-systematic-review
#20
REVIEW
Florian Kirsch
BACKGROUND: Disease management programs (DMPs) for chronic diseases are being increasingly implemented worldwide. OBJECTIVES: To present a systematic overview of the economic effects of DMPs with Markov models. The quality of the models is assessed, the method by which the DMP intervention is incorporated into the model is examined, and the differences in the structure and data used in the models are considered. METHODS: A literature search was conducted; the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed to ensure systematic selection of the articles...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"